Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Nektar Therapeutics before investing.

In this article, we go over a few key elements for understanding Nektar Therapeutics’s stock price such as:

• Nektar Therapeutics’s current stock price and volume
• Why Nektar Therapeutics’s stock price changed recently
• Upgrades and downgrades for NKTR from analysts
• NKTR’s stock price momentum as measured by its relative strength

About Nektar Therapeutics (NKTR)

Before we jump into Nektar Therapeutics’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Want to learn more about Nektar Therapeutics’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Nektar Therapeutics.

Nektar Therapeutics’s Stock Price as of Market Close

As of January 30, 2026, 4:00 PM, CST, Nektar Therapeutics’s stock price was $37.330.

Nektar Therapeutics is up 5.96% from its previous closing price of $35.230.

During the last market session, Nektar Therapeutics’s stock traded between $33.400 and $37.700. Currently, there are approximately 18.95 million shares outstanding for Nektar Therapeutics.

Nektar Therapeutics’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Nektar Therapeutics Stock Price History

Nektar Therapeutics’s (NKTR) price is currently down 11.71% so far this month.

During the month of January, Nektar Therapeutics’s stock price has reached a high of $45.340 and a low of $33.400.

Over the last year, Nektar Therapeutics has hit prices as high as $66.920 and as low as $6.480. Year to date, Nektar Therapeutics’s stock is down 11.71%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Nektar Therapeutics Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of January 30, 2026, there was 1 analyst who downgraded Nektar Therapeutics’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Nektar Therapeutics’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Nektar Therapeutics’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Nektar Therapeutics’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Nektar Therapeutics (NKTR) by visiting AAII Stock Evaluator.

Relative Price Strength of Nektar Therapeutics

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of January 30, 2026, Nektar Therapeutics has a weighted four-quarter relative price strength of 28.51%, which translates to a Momentum Score of 94 and is considered to be Very Strong.

Want to learn more about how Nektar Therapeutics is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Nektar Therapeutics Stock Price: Bottom Line

As of January 30, 2026, Nektar Therapeutics’s stock price is $37.330, which is up 5.96% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Nektar Therapeutics stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.